{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:02:31Z","timestamp":1767153751623,"version":"build-2238731810"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Turner Syndrome (TS) is associated with an increased risk of cardiovascular and metabolic complications. Furthermore, TS women need hormone replacement therapy (HRT), of which progestins can influence body weight. We aimed to analyze the metabolic and weight profile in a cohort of 111 TS women. They started receiving estrogen at 15.8 (\u00b13.6) years old, with no change in hypertension, dysglycemia, and dyslipidemia incidence but with a tendency to increase overweight (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009\n                    <jats:italic>0.054)<\/jats:italic>\n                    . As the first used type of progestin, most had received cycles of 10 days per month of medroxyprogesterone (MPA) or levonorgestrel (LNG), then shifted to micronized progesterone (MP), which has currently become the most used one. By multiple linear regression analysis, we found that the prolonged use of MPA, LNG, or MP showed no metabolic change except for weight gain. The percentage of annual BMI increment was positive for all progestins used in TS women (MPA 2.2\u2009\u00b1\u20092.2; LNG 0.2\u2009\u00b1\u20091.2; and MP 2.2\u2009\u00b1\u20092.6\u2009kg\/m2), but LNG seemed to best prevent on weight gain over time (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009\n                    <jats:italic>0.05)<\/jats:italic>\n                    . In conclusion, metabolic comorbidities are prevalent in TS even before the HRT regimen, and LNG performed better on less weight gain than MPA and MP in our cohort of the TS population.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-64992-4","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T06:04:11Z","timestamp":1589868251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Levonorgestrel correlates with less weight gain than other progestins during hormonal replacement therapy in Turner Syndrome patients"],"prefix":"10.1038","volume":"10","author":[{"given":"Andr\u00e9ia Latanza Gomes","family":"Mathez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-1693","authenticated-orcid":false,"given":"Patr\u00edcia Te\u00f3filo","family":"Monteagudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieda Therezinha","family":"do Nascimento Verreschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8516-966X","authenticated-orcid":false,"given":"Magnus R\u00e9gios","family":"Dias-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"64992_CR1","doi-asserted-by":"crossref","unstructured":"Gravholt, C. H. et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 177, G1\u2013G70, doi:10.1530\/EJE-17-0430 (2017).","DOI":"10.1530\/endoabs.49.GS1.1"},{"key":"64992_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1590\/S0004-27302011000800008","volume":"55","author":"PF Collett-Solberg","year":"2011","unstructured":"Collett-Solberg, P. F. et al. Endocrine diseases, perspectives and care in Turner syndrome. Arq. Bras. Endocrinol. Metab. 55, 550\u2013558 (2011).","journal-title":"Arq. Bras. Endocrinol. Metab."},{"key":"64992_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.fertnstert.2012.07.1104","volume":"98","author":"L Gonzalez","year":"2012","unstructured":"Gonzalez, L. & Witchel, S. F. The patient with Turner syndrome: puberty and medical management concerns. Fertil. Steril. 98, 780\u2013786, https:\/\/doi.org\/10.1016\/j.fertnstert.2012.07.1104 (2012).","journal-title":"Fertil. Steril."},{"key":"64992_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1590\/s0004-27302005000100019","volume":"49","author":"CH Gravholt","year":"2005","unstructured":"Gravholt, C. H. Epidemiological, endocrine and metabolic features in Turner syndrome. Arq. Bras. Endocrinol. Metab. 49, 145\u2013156, https:\/\/doi.org\/10.1590\/s0004-27302005000100019 (2005).","journal-title":"Arq. Bras. Endocrinol. Metab."},{"key":"64992_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000485321","volume":"89","author":"M Hankus","year":"2018","unstructured":"Hankus, M. et al. Prediction of Spontaneous Puberty in Turner Syndrome Based on Mid-Childhood Gonadotropin Concentrations, Karyotype, and Ovary Visualization: A Longitudinal Study. Horm. Res. Paediatr. 89, 90\u201397, https:\/\/doi.org\/10.1159\/000485321 (2018).","journal-title":"Horm. Res. Paediatr."},{"key":"64992_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1530\/EJE-11-0002","volume":"164","author":"R Giordano","year":"2011","unstructured":"Giordano, R. et al. Metabolic and cardiovascular outcomes in a group of adult patients with Turner\u2019s syndrome under hormonal replacement therapy. Eur. J. Endocrinol. 164, 819\u2013826, https:\/\/doi.org\/10.1530\/EJE-11-0002 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"64992_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1530\/EJE-07-0070","volume":"156","author":"CH Gravholt","year":"2007","unstructured":"Gravholt, C. H., Poulsen, H. E., Ott, P., Christiansen, J. S. & Vilstrup, H. Quantitative liver functions in Turner syndrome with and without hormone replacement therapy. Eur. J. Endocrinol. 156, 679\u2013686, https:\/\/doi.org\/10.1530\/EJE-07-0070 (2007).","journal-title":"Eur. J. Endocrinol."},{"key":"64992_CR8","first-page":"177","volume":"45","author":"C Lichiardopol","year":"2007","unstructured":"Lichiardopol, C. & Mota, M. Hypothyroidism in Turner syndrome. Rom. J. Intern. Med. 45, 177\u2013182 (2007).","journal-title":"Rom. J. Intern. Med."},{"key":"64992_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s12020-011-9504-z","volume":"40","author":"AD Baldin","year":"2011","unstructured":"Baldin, A. D. et al. Growth hormone effect on body composition in Turner syndrome. Endocrine 40, 486\u2013491, https:\/\/doi.org\/10.1007\/s12020-011-9504-z (2011).","journal-title":"Endocrine"},{"key":"64992_CR10","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/EJE-13-0900","volume":"170","author":"A Gawlik","year":"2014","unstructured":"Gawlik, A. & Malecka-Tendera, E. Transitions in endocrinology: treatment of Turner\u2019s syndrome during transition. Eur. J. Endocrinol. 170, R57\u201374, https:\/\/doi.org\/10.1530\/EJE-13-0900 (2014).","journal-title":"Eur. J. Endocrinol."},{"key":"64992_CR11","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1210\/jc.2017-02183","volume":"103","author":"KO Klein","year":"2018","unstructured":"Klein, K. O. et al. Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations. J. Clin. Endocrinol. Metab. 103, 1790\u20131803, https:\/\/doi.org\/10.1210\/jc.2017-02183 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"64992_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.contraception.2013.03.004","volume":"88","author":"Z Vickery","year":"2013","unstructured":"Vickery, Z. et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 88, 503\u2013508, https:\/\/doi.org\/10.1016\/j.contraception.2013.03.004 (2013).","journal-title":"Contraception"},{"key":"64992_CR13","doi-asserted-by":"publisher","unstructured":"Lopez, L. M. et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev, CD008815, https:\/\/doi.org\/10.1002\/14651858.CD008815.pub3 (2013).","DOI":"10.1002\/14651858.CD008815.pub3"},{"key":"64992_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","volume":"61","author":"AE Schindler","year":"2008","unstructured":"Schindler, A. E. et al. Classification and pharmacology of progestins. Maturitas 61, 171\u2013180, https:\/\/doi.org\/10.1016\/j.maturitas.2008.11.013 (2008).","journal-title":"Maturitas"},{"key":"64992_CR15","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1161\/01.HYP.0000242482.57186.e8","volume":"48","author":"PA Arias-Loza","year":"2006","unstructured":"Arias-Loza, P. A. et al. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension 48, 994\u20131001, https:\/\/doi.org\/10.1161\/01.HYP.0000242482.57186.e8 (2006).","journal-title":"Hypertension"},{"issue":"Suppl 2","key":"64992_CR16","first-page":"739","volume":"9","author":"C Trolle","year":"2012","unstructured":"Trolle, C., Mortensen, K. H., Hjerrild, B. E., Cleemann, L. & Gravholt, C. H. Clinical care of adult Turner syndrome\u2013new aspects. Pediatr. Endocrinol. Rev. 9(Suppl 2), 739\u2013749 (2012).","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"64992_CR17","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1210\/jc.2012-4243","volume":"98","author":"L Torres-Santiago","year":"2013","unstructured":"Torres-Santiago, L. et al. Metabolic effects of oral versus transdermal 17beta-estradiol (E(2)): a randomized clinical trial in girls with Turner syndrome. J. Clin. Endocrinol. Metab. 98, 2716\u20132724, https:\/\/doi.org\/10.1210\/jc.2012-4243 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"64992_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bbacli.2015.04.005","volume":"3","author":"M Mavinkurve","year":"2015","unstructured":"Mavinkurve, M. & O\u2019Gorman, C. S. Cardiometabolic and vascular risks in young and adolescent girls with Turner syndrome. BBA Clin. 3, 304\u2013309, https:\/\/doi.org\/10.1016\/j.bbacli.2015.04.005 (2015).","journal-title":"BBA Clin."},{"key":"64992_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fendo.2018.00027","volume":"9","author":"Y Lebenthal","year":"2018","unstructured":"Lebenthal, Y. et al. The Natural History of Metabolic Comorbidities in Turner Syndrome from Childhood to Early Adulthood: Comparison between 45,X Monosomy and Other Karyotypes. Front. Endocrinol. 9, 27, https:\/\/doi.org\/10.3389\/fendo.2018.00027 (2018).","journal-title":"Front. Endocrinol."},{"key":"64992_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/liv.12007","volume":"33","author":"D Roulot","year":"2013","unstructured":"Roulot, D. Liver involvement in Turner syndrome. Liver Int. 33, 24\u201330, https:\/\/doi.org\/10.1111\/liv.12007 (2013).","journal-title":"Liver Int."},{"key":"64992_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.23736\/S0391-1977.16.02570-0","volume":"42","author":"G Mintziori","year":"2017","unstructured":"Mintziori, G., Poulakos, P., Tsametis, C. & Goulis, D. G. Hypogonadism and non-alcoholic fatty liver disease. Minerva Endocrinol. 42, 145\u2013150, https:\/\/doi.org\/10.23736\/S0391-1977.16.02570-0 (2017).","journal-title":"Minerva Endocrinol."},{"key":"64992_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/cen.13044","volume":"85","author":"T Reinehr","year":"2016","unstructured":"Reinehr, T. et al. Weight gain in Turner Syndrome: association to puberty induction? - longitudinal analysis of KIGS data. Clin. Endocrinol. 85, 85\u201391, https:\/\/doi.org\/10.1111\/cen.13044 (2016).","journal-title":"Clin. Endocrinol."},{"key":"64992_CR23","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1210\/jc.2011-1449","volume":"96","author":"M Taboada","year":"2011","unstructured":"Taboada, M. et al. Pharmacokinetics and pharmacodynamics of oral and transdermal 17beta estradiol in girls with Turner syndrome. J. Clin. Endocrinol. Metab. 96, 3502\u20133510, https:\/\/doi.org\/10.1210\/jc.2011-1449 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"64992_CR24","doi-asserted-by":"publisher","first-page":"7060","DOI":"10.1158\/0008-5472.CAN-14-1784","volume":"74","author":"EE Sweeney","year":"2014","unstructured":"Sweeney, E. E., Fan, P. & Jordan, V. C. Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women\u2019s health initiative study. Cancer Res. 74, 7060\u20137068, https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1784 (2014).","journal-title":"Cancer Res."},{"key":"64992_CR25","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1111\/bph.12814","volume":"171","author":"T Freudenberger","year":"2014","unstructured":"Freudenberger, T. et al. Synthetic gestagens exert differential effects on arterial thrombosis and aortic gene expression in ovariectomized apolipoprotein E-deficient mice. Br. J. Pharmacol. 171, 5032\u20135048, https:\/\/doi.org\/10.1111\/bph.12814 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"64992_CR26","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1210\/en.2007-1612","volume":"149","author":"C Otto","year":"2008","unstructured":"Otto, C. et al. Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. Endocrinology 149, 3952\u20133959, https:\/\/doi.org\/10.1210\/en.2007-1612 (2008).","journal-title":"Endocrinology"},{"key":"64992_CR27","doi-asserted-by":"publisher","unstructured":"Lopez, L. M. et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev, CD008815, https:\/\/doi.org\/10.1002\/14651858.CD008815.pub4 (2016).","DOI":"10.1002\/14651858.CD008815.pub4"},{"key":"64992_CR28","first-page":"715","volume":"89","author":"JR Yancey","year":"2014","unstructured":"Yancey, J. R. & Raleigh, M. Progestin-only contraceptives: effects on weight. Am. Fam. Physician 89, 715\u2013716 (2014).","journal-title":"Am. Fam. Physician"},{"key":"64992_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijgo.2008.05.017","volume":"103","author":"S Ozdemir","year":"2008","unstructured":"Ozdemir, S., Gorkemli, H., Gezginc, K., Ozdemir, M. & Kiyici, A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int. J. Gynaecol. Obstet. 103, 44\u201349, https:\/\/doi.org\/10.1016\/j.ijgo.2008.05.017 (2008).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"64992_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-166","volume":"8","author":"XD Fu","year":"2008","unstructured":"Fu, X. D. et al. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer 8, 166, https:\/\/doi.org\/10.1186\/1471-2407-8-166 (2008).","journal-title":"BMC Cancer"},{"key":"64992_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/13625187.2014.951433","volume":"20","author":"W Modesto","year":"2015","unstructured":"Modesto, W., de Nazare Silva dos Santos, P., Correia, V. M., Borges, L. & Bahamondes, L. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use. Eur. J. Contracept. Reprod. Health Care 20, 57\u201363, https:\/\/doi.org\/10.3109\/13625187.2014.951433 (2015).","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"64992_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ijgo.12455","volume":"141","author":"MV Dragoman","year":"2018","unstructured":"Dragoman, M. V. et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int. J. Gynaecol. Obstet. 141, 287\u2013294, https:\/\/doi.org\/10.1002\/ijgo.12455 (2018).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"64992_CR33","doi-asserted-by":"publisher","first-page":"d6423","DOI":"10.1136\/bmj.d6423","volume":"343","author":"O Lidegaard","year":"2011","unstructured":"Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E. & Lokkegaard, E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 343, d6423, https:\/\/doi.org\/10.1136\/bmj.d6423 (2011).","journal-title":"BMJ"},{"key":"64992_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1476-511X-11-133","volume":"11","author":"G Casanova","year":"2012","unstructured":"Casanova, G. & Spritzer, P. M. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial. Lipids Health Dis. 11, 133, https:\/\/doi.org\/10.1186\/1476-511X-11-133 (2012).","journal-title":"Lipids Health Dis."},{"key":"64992_CR35","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1210\/jc.2008-1049","volume":"93","author":"MJ Schoemaker","year":"2008","unstructured":"Schoemaker, M. J. et al. Mortality in women with turner syndrome in Great Britain: a national cohort study. J. Clin. Endocrinol. Metab. 93, 4735\u20134742, https:\/\/doi.org\/10.1210\/jc.2008-1049 (2008).","journal-title":"J. Clin. Endocrinol. Metab."}],"updated-by":[{"DOI":"10.1038\/s41598-020-69839-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64992-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T06:48:37Z","timestamp":1670309317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64992-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64992"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64992-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8298"}}